Dentinal Hypersensitivity
2
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
ViiV HealthcareNC - Durham
2 programs1
1
5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifricePhase 2
Potassium NitratePhase 1
GSKLONDON, United Kingdom
1 program5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifricePHASE_21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
GSK5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
Pierre FabreV063B-DP3003
Clinical Trials (2)
Total enrollment: 195 patients across 2 trials
Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity
Start: Jan 2013Est. completion: May 2013140 patients
Phase 2Completed
Oral and Dental Tolerance and Efficacy on Dentinal Hypersensitivity of a Dental Gel, on Adults
Start: Sep 2015Est. completion: Jun 201655 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.